Case reports of ECMO-integrated CytoSorb® have documented brisk interleukin-6 clearance and catecholamine sparing [14], and the multi-centre CytoSorb Therapy in COVID-19 Registry reported 74% 90-day survival when adsorption was initiated within 24 h of cannulation [15]. Here, IL6 is linked to COVID-19.